


PHARMACEUTICAL 2018

Statera Biopharma Inc. Rank 288 of 349







PHARMACEUTICAL 2018



Statera Biopharma Inc. Rank 288 of 349

The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Statera Biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 314% points.

The company's Economic Capital Ratio, given in the ranking table, is -531%, being 253% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	9,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,213
Liabilities, Non-Current	7.5
Other Assets	31
Other Compr. Net Income	184
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,294
Property and Equipment	19
Research and Development	5,048
Revenues	0
Selling, General and Administrative Expense	2,501

Output Variable	Value in 1000 USD
Assets	9,629
Liabilities	2,221
Expenses	7,549
Stockholders Equity	7,408
Net Income	-9,843
Comprehensive Net Income	-9,751
Economic Capital Ratio	-531%

